CoChat
Sign Up
Cited by 58Estrogen and related hormone effectsBreast Cancer Treatment StudiesUbiquitin and proteasome pathways

UCH-L1-mediated Down-regulation of Estrogen Receptor α Contributes to Insensitivity to Endocrine Therapy for Breast Cancer

Open access
Chen, Xi-Sha, Wang, Kuan-Song, Guo, Wei, Li, Lan-Ya, Yu, Pian, Sun, Xin-Yuan, Wang, Hai-Yan, Guan, Yi-Di +9 more·2020·Theranostics
DOI 10.7150/thno.39814PMC PMC6993235
Open this paper in CoChat — free account

Abstract

: Our results reveal an important role of UCH-L1 in modulating ERα status and demonstrate the involvement of UCH-L1-EGFR signaling pathway, suggesting that UCH-L1 may serve as a novel adjuvant target for treatment of hormone therapy-insensitive breast cancers. Targeting UCH-L1 to sensitize ER negative breast cancer to anti-estrogen therapy might represent a new therapeutic strategy that warrants further exploration.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7150/thno.39814

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Tamoxifen acts by competitively blocking the binding of estrogen to ERα and has significantly improved prognosis in patients with ER+ breast cancer.

    “Among these agents, Tamoxifen, a selective estrogen receptor modulator, acts by competitively blocking the binding of estrogen to ERα and has significantly improved prognosis in patients with ER+ breast cancer15,21,22.”

    From Harnessing artificial intelligence to identify Bufalin as a molecular glue degrader of estrogen receptor alpha (2025) · cites this paper as [21]

    The Introduction says ERα-positive breast cancers respond to tamoxifen and usually have a better prognosis; the Discussion identifies tamoxifen as a selective estrogen receptor modulator. Neither passage states that tamoxifen competitively blocks estrogen binding to ERα or establishes that tamoxifen significantly improved patients’ prognosis. Page numbers were not available in our copy. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

  • Our previous study has reported that the UCH-L1 inhibitor LDN significantly enhanced the efficacy of Tamoxifen both in vivo and in vitro.

    “Our previous study has reported that the UCH-L1 inhibitor LDN significantly enhanced the efficacy of Tamoxifen both in vivo and in vitro21.”

    From Harnessing artificial intelligence to identify Bufalin as a molecular glue degrader of estrogen receptor alpha (2025) · cites this paper as [21]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 65

  1. [1]Bray F Ferlay J Soerjomataram I Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 2018 30207593
  2. [2]Sherr CJ Cancer cell cycles Science 1996 274 1672 7 8939849
  3. [3]Wang G Gormley M Qiao J Cyclin D1-mediated microRNA expression signature predicts breast cancer outcome Theranostics 2018 8 2251 63 29721077 PMC5928887
  4. [5]Gronemeyer H Gustafsson JA Laudet V Principles for modulation of the nuclear receptor superfamily Nat Rev Drug Discov 2004 3 950 64 15520817
  5. [6]Jiang G Wang X Sheng D Cooperativity of co-factor NR2F2 with Pioneer Factors GATA3, FOXA1 in promoting ERalpha function Theranostics 2019 9 6501 16 31588232 PMC6771234
  6. [7]Kao TL Kuan YP Cheng WC Estrogen receptors orchestrate cell growth and differentiation to facilitate liver regeneration Theranostics 2018 8 2672 82 29774067 PMC5957001
  7. [8]Couse JF Korach KS Reproductive phenotypes in the estrogen receptor-alpha knockout mouse Ann Endocrinol (Paris) 1999 60 143 8 10456188
  8. [9]Couse JF Lindzey J Grandien K Gustafsson JA Korach KS Tissue distribution and quantitative analysis of estrogen receptor-alpha (ERalpha) and estrogen receptor-beta (ERbeta) messenger ribonucleic acid in the wild-type and ERalpha-knockout mouse Endocrinology 1997 138 4613 21 9348186
  9. [10]Saji S Jensen EV Nilsson S Estrogen receptors alpha and beta in the rodent mammary gland Proc Natl Acad Sci U S A 2000 97 337 42 10618419 PMC26664
  10. [11]Mallepell S Krust A Chambon P Brisken C Paracrine signaling through the epithelial estrogen receptor alpha is required for proliferation and morphogenesis in the mammary gland Proc Natl Acad Sci U S A 2006 103 2196 201 16452162 PMC1413744
  11. [12]Regan MM Viale G Mastropasqua MG Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays J Natl Cancer Inst 2006 98 1571 81 17077359
  12. [13]Kuukasjarvi T Kononen J Helin H Holli K Isola J Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy J Clin Oncol 1996 14 2584 9 8823339
  13. [14]McGuire WL Osborne CK Clark GM Knight WA 3rd Steroid hormone receptors and carcinoma of the breast Am J Physiol 1982 243 E99 102 7114210
  14. [15]Johnston SR Saccani-Jotti G Smith IE Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer Cancer Res 1995 55 3331 8 7614468
  15. [16]Newby JC Johnston SR Smith IE Dowsett M Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer Clin Cancer Res 1997 3 1643 51 9815855
  16. [17]Dou XW Liang YK Lin HY Notch3 Maintains Luminal Phenotype and Suppresses Tumorigenesis and Metastasis of Breast Cancer via Trans-Activating Estrogen Receptor-alpha Theranostics 2017 7 4041 56 29109797 PMC5667424
  17. [18]Creighton CJ Hilger AM Murthy S Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors Cancer Res 2006 66 3903 11 16585219
  18. [19]Bayliss J Hilger A Vishnu P Diehl K El-Ashry D Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response Clin Cancer Res 2007 13 7029 36 18056179
  19. [20]Grabinski N Mollmann K Milde-Langosch K AKT3 regulates ErbB2, ErbB3 and estrogen receptor alpha expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice Cell Signal 2014 26 1021 9 24463007
  20. [21]Li Y Meeran SM Patel SN Epigenetic reactivation of estrogen receptor-alpha (ERalpha) by genistein enhances hormonal therapy sensitivity in ERalpha-negative breast cancer Mol Cancer 2013 12 9 23379261 PMC3577460
  21. [22]Roswall P Bocci M Bartoschek M Microenvironmental control of breast cancer subtype elicited through paracrine platelet-derived growth factor-CC signaling Nat Med 2018 24 463 73 29529015 PMC5896729
  22. [23]Larsen CN Krantz BA Wilkinson KD Substrate specificity of deubiquitinating enzymes: ubiquitin C-terminal hydrolases Biochemistry 1998 37 3358 68 9521656
  23. [24]Doran JF Jackson P Kynoch PA Thompson RJ Isolation of PGP 9.5, a new human neurone-specific protein detected by high-resolution two-dimensional electrophoresis J Neurochem 1983 40 1542 7 6343558
  24. [25]Setsuie R Wada K The functions of UCH-L1 and its relation to neurodegenerative diseases Neurochem Int 2007 51 105 11 17586089
  25. [26]Tezel E Hibi K Nagasaka T Nakao A PGP9.5 as a prognostic factor in pancreatic cancer Clin Cancer Res 2000 6 4764 7 11156232
  26. [27]Leiblich A Cross SS Catto JW Human prostate cancer cells express neuroendocrine cell markers PGP 9.5 and chromogranin A Prostate 2007 67 1761 9 17929277
  27. [28]Takano T Miyauchi A Matsuzuka F PGP9.5 mRNA could contribute to the molecular-based diagnosis of medullary thyroid carcinoma Eur J Cancer 2004 40 614 8 14962731
  28. [29]Mizukami H Shirahata A Goto T PGP9.5 methylation as a marker for metastatic colorectal cancer Anticancer Res 2008 28 2697 700 19035297
  29. [30]Brichory F Beer D Le Naour F Giordano T Hanash S Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer Cancer Res 2001 61 7908 12 11691811
  30. [31]Kim HJ Kim YM Lim S Ubiquitin C-terminal hydrolase-L1 is a key regulator of tumor cell invasion and metastasis Oncogene 2009 28 117 27 18820707
  31. [32]Ma Y Zhao M Zhong J Proteomic profiling of proteins associated with lymph node metastasis in colorectal cancer J Cell Biochem 2010 110 1512 9 20524204
  32. [33]Jang MJ Baek SH Kim JH UCH-L1 promotes cancer metastasis in prostate cancer cells through EMT induction Cancer Lett 2011 302 128 35 21310527
  33. [34]Luo Y He J Yang C UCH-L1 promotes invasion of breast cancer cells through activating Akt signaling pathway J Cell Biochem 2018 119 691 700 28636190 PMC5705264
  34. [35]Kim HJ Magesh V Lee JJ Ubiquitin C-terminal hydrolase-L1 increases cancer cell invasion by modulating hydrogen peroxide generated via NADPH oxidase 4 Oncotarget 2015 6 16287 303 25915537 PMC4599270
  35. [36]Yamazaki T Hibi K Takase T PGP9.5 as a marker for invasive colorectal cancer Clin Cancer Res 2002 8 192 5 11801558
  36. [37]Schroder C Milde-Langosch K Gebauer F Prognostic relevance of ubiquitin C-terminal hydrolase L1 (UCH-L1) mRNA and protein expression in breast cancer patients J Cancer Res Clin Oncol 2013 139 1745 55 23996067 PMC11824684
  37. [38]Wang W Zou L Zhou D Overexpression of ubiquitin carboxyl terminal hydrolase-L1 enhances multidrug resistance and invasion/metastasis in breast cancer by activating the MAPK/Erk signaling pathway Mol Carcinog 2016 55 1329 42 26293643
  38. [39]Ning K Wang T Sun X UCH-L1-containing exosomes mediate chemotherapeutic resistance transfer in breast cancer J Surg Oncol 2017 115 932 40 28334432
  39. [40]Akishima-Fukasawa Y Ino Y Nakanishi Y Significance of PGP9.5 expression in cancer-associated fibroblasts for prognosis of colorectal carcinoma Am J Clin Pathol 2010 134 71 9 20551269
  40. [41]Miyoshi Y Nakayama S Torikoshi Y High expression of ubiquitin carboxy-terminal hydrolase-L1 and -L3 mRNA predicts early recurrence in patients with invasive breast cancer Cancer Sci 2006 97 523 9 16734731 PMC11160066
  41. [42]Goldhirsch A Winer EP Coates AS Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 Ann Oncol 2013 24 2206 23 23917950 PMC3755334
  42. [43]Coates AS Winer EP Goldhirsch A Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 Ann Oncol 2015 26 1533 46 25939896 PMC4511219
  43. [45]Desmedt C Piette F Loi S Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series Clin Cancer Res 2007 13 3207 14 17545524
  44. [46]Servant N Bollet MA Halfwerk H Search for a gene expression signature of breast cancer local recurrence in young women Clin Cancer Res 2012 18 1704 15 22271875
  45. [47]Jin Y Zhang W Xu J UCH-L1 involved in regulating the degradation of EGFR and promoting malignant properties in drug-resistant breast cancer Int J Clin Exp Pathol 2015 8 12500 8 26722437 PMC4680382
  46. [48]Sainsbury JR Farndon JR Sherbet GV Harris AL Epidermal-growth-factor receptors and oestrogen receptors in human breast cancer Lancet 1985 1 364 6 2857419
  47. [49]Stoica A Saceda M Doraiswamy VL Coleman C Martin MB Regulation of estrogen receptor-alpha gene expression by epidermal growth factor J Endocrinol 2000 165 371 8 10810301
  48. [50]Oh AS Lorant LA Holloway JN Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells Mol Endocrinol 2001 15 1344 59 11463858
  49. [51]Holloway JN Murthy S El-Ashry D A cytoplasmic substrate of mitogen-activated protein kinase is responsible for estrogen receptor-alpha down-regulation in breast cancer cells: the role of nuclear factor-kappaB Mol Endocrinol 2004 18 1396 410 15056731
  50. [52]Nakshatri H Bhat-Nakshatri P Martin DA Goulet RJ Jr Sledge GW Jr Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth Mol Cell Biol 1997 17 3629 39 9199297 PMC232215
  51. [53]Brinkman JA El-Ashry D ER re-expression and re-sensitization to endocrine therapies in ER-negative breast cancers J Mammary Gland Biol Neoplasia 2009 14 67 78 19263197
  52. [54]Lurje G Lenz HJ EGFR signaling and drug discovery Oncology 2009 77 400 10 20130423
  53. [55]Guo S Sonenshein GE Forkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is repressed by the Her-2/neu/phosphatidylinositol 3-kinase/Akt signaling pathway Mol Cell Biol 2004 24 8681 90 15367686 PMC516736
  54. [56]Li L Tao Q Jin H The tumor suppressor UCHL1 forms a complex with p53/MDM2/ARF to promote p53 signaling and is frequently silenced in nasopharyngeal carcinoma Clin Cancer Res 2010 16 2949 58 20395212
  55. [57]Mandelker DL Yamashita K Tokumaru Y PGP9.5 promoter methylation is an independent prognostic factor for esophageal squamous cell carcinoma Cancer Res 2005 65 4963 8 15930319
  56. [58]Yamashita K Park HL Kim MS PGP9.5 methylation in diffuse-type gastric cancer Cancer Res 2006 66 3921 7 16585221
  57. [59]Kagara I Enokida H Kawakami K CpG hypermethylation of the UCHL1 gene promoter is associated with pathogenesis and poor prognosis in renal cell carcinoma J Urol 2008 180 343 51 18499164
  58. [60]Tokumaru Y Yamashita K Kim MS The role of PGP9.5 as a tumor suppressor gene in human cancer Int J Cancer 2008 123 753 9 18512240 PMC3069849
  59. [61]Yu J Tao Q Cheung KF Epigenetic identification of ubiquitin carboxyl-terminal hydrolase L1 as a functional tumor suppressor and biomarker for hepatocellular carcinoma and other digestive tumors Hepatology 2008 48 508 18 18666234
  60. [62]Okochi-Takada E Nakazawa K Wakabayashi M Silencing of the UCHL1 gene in human colorectal and ovarian cancers Int J Cancer 2006 119 1338 44 16642472
  61. [63]You R Hua YJ Liu YP Concurrent Chemoradiotherapy with or without Anti-EGFR-Targeted Treatment for Stage II-IVb Nasopharyngeal Carcinoma: Retrospective Analysis with a Large Cohort and Long Follow-up Theranostics 2017 7 2314 24 28740554 PMC5505063
  62. [64]Mitsudomi T Yatabe Y Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer Cancer Sci 2007 98 1817 24 17888036 PMC11159145
  63. [65]Park SJ Kim HT Lee DH Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation Lung Cancer 2012 77 556 60 22677429
  64. [66]Kobayashi S Boggon TJ Dayaram T EGFR mutation and resistance of non-small-cell lung cancer to gefitinib N Engl J Med 2005 352 786 92 15728811
  65. [67]Yu HA Arcila ME Rekhtman N Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers Clin Cancer Res 2013 19 2240 7 23470965 PMC3630270

Cited by

Sorted by citations

Authors
Chen, X.-S., Wang, K.-S., Guo, W., Li, L.-Y., Yu, P., Sun, X.-Y., Wang, H.-Y., Guan, Y.-D., Tao, Y.-G., Ding, B.-N., Yin, M.-Z., Ren, X.-C., Zhang, Y., Chen, C.-S., Ye, Y.-C., Yang, J.-M., & Cheng, Y.
Affiliations
  • Central South University (CN)
  • Soochow University (CN)
Corresponding author
Cheng, Yan
ORCID
Venue
Theranostics
Publisher
Ivyspring International Publisher
Published
2020
Volume
10
Issue
4
Pages
1833-1848
ISSN
1838-7640 (ISSN-L)
DOI
10.7150/thno.39814
PMC
PMC6993235
OpenAlex
W2997627571
Cited by
58
References
2
Citations by year
2026: 6 · 2025: 7 · 2024: 19 · 2023: 10 · 2022: 10 · 2021: 4 · 2020: 2
FWCI
3.81
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Theranostics (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Estrogen and related hormone effects
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
Keywords
UCHL1, estrogen receptor alpha, breast cancer, endocrine therapy resistance, estrogen receptor-negative breast cancer, antiestrogen therapy
MeSH terms
Fulvestrant, Animals, Breast Neoplasms, Estrogen Antagonists, Female, Humans, Mice, Nude, Tamoxifen, Down-Regulation, Up-Regulation, Drug Resistance, Neoplasm, Ubiquitin Thiolesterase, Estrogen Receptor alpha, Mice, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review